Chemours Sued for Securities Fraud Over Opteon Demand Issues Following 18% Stock Drop

Chemours Co faces a class action lawsuit alleging securities fraud regarding Opteon product demand misrepresentation following an 18.63% stock drop. Investors have until December 7, 2026, to seek appointment as lead plaintiff.